Regeneron's shares surged 13.55% following a strong third-quarter earnings report that beat revenue and earnings expectations. This rise positively impacted health care ETFs like XLV, IBB, and XBI, which hold Regeneron shares, contributing to their gains. Investors should note the overlap risk in ETFs holding large biotech stocks and watch upcoming catalysts such as FDA decisions and Sanofi payments that could further influence these funds.
As of Oct 30, 2026 22:31 WIB, Regeneron Pharmaceuticals Inc (REGN) trades at USD 917.33 on Pluang, up 12.04% in the last day, closely matching the article's noted surge. Health Care Select Sector SPDR Fund (XLV), which includes Regeneron shares, is also up 0.96% at USD 185.80. Meanwhile, the State Street SPDR S&P Biotech ETF (XBI) is down 1.05% at USD 156.13. Regeneron's market cap stands at $84.30 billion, highlighting its significant role in these ETFs.
Regeneron Pharmaceuticals' stock surged 12% after reporting a 36% revenue increase to $5.1 billion in Q3 2026, beating analyst expectations. The boost was largely due to its partnership with Sanofi, with Dupixent sales rising 35%, and record sales of...
Regeneron reported a 36% revenue increase to $5.1 billion in Q3 2026, with record sales for Dupixent, EYLEA HD, and Libtayo. GAAP EPS rose 35% to $18.45, and non-GAAP EPS jumped 70% to $20.07. The company expanded its collaboration with Sanofi, secur...
Regeneron will report its Q3 earnings on October 30, marking the first quarter it fully books its share of Dupixent profits from Sanofi after repaying a $3.1 billion development balance. This change is expected to significantly boost collaboration re...
Regeneron Pharmaceuticals has extended its agreement with the U.S. government's BARDA to supply additional doses of Inmazeb, an FDA-approved antibody treatment for Ebola caused by Orthoebolavirus zairense. The expanded deal, valued at approximately $...
